Detalles de la búsqueda
1.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
N Engl J Med
; 388(7): 595-608, 2023 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36791160
2.
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
Clin Infect Dis
; 78(1): 202-209, 2024 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37698366
3.
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Clin Infect Dis
; 2024 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38253338
4.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
BMC Infect Dis
; 20(1): 426, 2020 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32552685
5.
Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
BMC Infect Dis
; 15: 409, 2015 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26437712
6.
Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
BMC Infect Dis
; 13: 116, 2013 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23510357
7.
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Nat Med
; 27(1): 106-114, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33288923
8.
Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study.
BMC Fam Pract
; 11: 22, 2010 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20230601
9.
Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.
Hum Vaccin Immunother
; 16(6): 1272-1279, 2020 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32401600
10.
Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
Vaccine
; 38(22): 3902-3908, 2020 05 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32284274
11.
Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age.
Hum Vaccin Immunother
; 16(6): 1280-1291, 2020 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32598244
12.
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.
Lancet Infect Dis
; 20(1): 80-91, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31630990
13.
Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
Pediatr Infect Dis J
; 38(6): 643-650, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31116180
14.
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.
Immunohorizons
; 3(4): 133-148, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31032479
15.
Antibody persistence and booster response 68â¯months after vaccination at 2-10â¯years of age with one dose of MenACWY-TT conjugate vaccine.
Vaccine
; 36(23): 3286-3295, 2018 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29724511
16.
MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial.
Vaccine
; 36(27): 3967-3975, 2018 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29789243
17.
Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
Vaccine
; 36(28): 4102-4111, 2018 06 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29784470
18.
Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.
Vaccine
; 36(14): 1908-1916, 2018 03 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29503112
19.
Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Vaccine
; 36(17): 2356-2363, 2018 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29576307
20.
Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Vaccine
; 36(31): 4750-4758, 2018 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-29960800